E Søndergaard1, L P Sørensen2, I Rahbek2, L C Gormsen3, J S Christiansen2, S Nielsen2. 1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus C, Denmark. esbens@dadlnet.dk. 2. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus C, Denmark. 3. Department of Clinical Physiology and Nuclear Medicine, Aarhus University Hospital, Aarhus, Denmark.
Abstract
AIMS/HYPOTHESIS: Type 2 diabetes is characterised by insulin resistance and increased post-absorptive secretion of VLDL-triacylglycerol (VLDL-TAG). Whether postprandial suppression of endogenous VLDL-TAG secretion is abnormal--a finding that would link hyperlipidaemia and type 2 diabetes--remains unclear. METHODS: Eight type 2 diabetic men and eight healthy men were studied before and after a fat-free test meal (40% of resting energy expenditure). VLDL-TAG kinetics were assessed using a primed-constant infusion of ex vivo labelled [1-(14)C]triolein VLDL-TAG using non-steady-state calculations. RESULTS: Type 2 diabetic men had a higher basal VLDL-TAG secretion rate and concentration than healthy men (mean ± SD secretion rate 137 ± 61 vs 78 ± 30 μmol/min, respectively [p = 0.03]; median concentration 1.03 [range 0.58-1.75] vs 0.33 [0.13-1.14] mmol/l, respectively [p < 0.01]). Postprandially, the VLDL-TAG secretion rate decreased in healthy men (p < 0.01), but remained unchanged in diabetic men (p = 0.47). The VLDL-TAG concentration increased in diabetic men and decreased in healthy men postprandially (p < 0.05). The difference in VLDL-TAG secretion rate between the two groups approached significance (p = 0.06) and the relative change in VLDL-TAG secretion rate was significantly different (p = 0.01) between the two groups. Basal VLDL-TAG clearance was significantly lower in diabetic men (diabetic men 133 [49-390] ml/min; healthy controls 215 [137-933] ml/min [p < 0.05]). After meal ingestion, clearance decreased in healthy men (p = 0.03), but was unchanged in diabetic men (p = 0.58). CONCLUSIONS/ INTERPRETATION: Obese type 2 diabetic men have impaired postprandial suppression of VLDL-TAG secretion compared with lean healthy men, contributing to their postprandial lipaemia and hypertriacylglycerolaemia.
AIMS/HYPOTHESIS: Type 2 diabetes is characterised by insulin resistance and increased post-absorptive secretion of VLDL-triacylglycerol (VLDL-TAG). Whether postprandial suppression of endogenous VLDL-TAG secretion is abnormal--a finding that would link hyperlipidaemia and type 2 diabetes--remains unclear. METHODS: Eight type 2 diabeticmen and eight healthy men were studied before and after a fat-free test meal (40% of resting energy expenditure). VLDL-TAG kinetics were assessed using a primed-constant infusion of ex vivo labelled [1-(14)C]triolein VLDL-TAG using non-steady-state calculations. RESULTS: Type 2 diabeticmen had a higher basal VLDL-TAG secretion rate and concentration than healthy men (mean ± SD secretion rate 137 ± 61 vs 78 ± 30 μmol/min, respectively [p = 0.03]; median concentration 1.03 [range 0.58-1.75] vs 0.33 [0.13-1.14] mmol/l, respectively [p < 0.01]). Postprandially, the VLDL-TAG secretion rate decreased in healthy men (p < 0.01), but remained unchanged in diabeticmen (p = 0.47). The VLDL-TAG concentration increased in diabeticmen and decreased in healthy men postprandially (p < 0.05). The difference in VLDL-TAG secretion rate between the two groups approached significance (p = 0.06) and the relative change in VLDL-TAG secretion rate was significantly different (p = 0.01) between the two groups. Basal VLDL-TAG clearance was significantly lower in diabeticmen (diabeticmen 133 [49-390] ml/min; healthy controls 215 [137-933] ml/min [p < 0.05]). After meal ingestion, clearance decreased in healthy men (p = 0.03), but was unchanged in diabeticmen (p = 0.58). CONCLUSIONS/ INTERPRETATION:Obese type 2 diabeticmen have impaired postprandial suppression of VLDL-TAG secretion compared with lean healthy men, contributing to their postprandial lipaemia and hypertriacylglycerolaemia.
Authors: R Malmström; C J Packard; M Caslake; D Bedford; P Stewart; H Yki-Järvinen; J Shepherd; M R Taskinen Journal: Diabetes Date: 1998-05 Impact factor: 9.461
Authors: Leanne Hodson; Alex S T Bickerton; Siobhán E McQuaid; Rachel Roberts; Fredrik Karpe; Keith N Frayn; Barbara A Fielding Journal: Diabetes Date: 2007-06-29 Impact factor: 9.461
Authors: Demidmaa Tuvdendorj; Xiao-jun Zhang; David L Chinkes; Lijian Wang; Zhanpin Wu; Noe A Rodriguez; David N Herndon; Robert R Wolfe Journal: Metabolism Date: 2015-01-08 Impact factor: 8.694
Authors: Rakel F Johansen; Esben Søndergaard; Lars Peter Sørensen; Anne Grethe Jurik; Jens S Christiansen; Søren Nielsen Journal: Diabetologia Date: 2016-01-19 Impact factor: 10.122
Authors: Elisa Álvarez Hernández; Sabine Kahl; Anett Seelig; Paul Begovatz; Martin Irmler; Yuliya Kupriyanova; Bettina Nowotny; Peter Nowotny; Christian Herder; Cristina Barosa; Filipa Carvalho; Jan Rozman; Susanne Neschen; John G Jones; Johannes Beckers; Martin Hrabě de Angelis; Michael Roden Journal: J Clin Invest Date: 2017-01-23 Impact factor: 14.808